Novo Nordisk cuts profit forecast as new CEO faces rocky start

Novo Nordisk has significantly lowered its full-year profit forecast to 4-7% growth from a previous 10-16%, and sales growth to 8-11%, presenting an immediate challenge for new CEO Mike Doustdar. This downward revision is driven by slowing sales and intensified competition in the obesity drug market, notably from Eli Lilly's Mounjaro, contributing to a more than 50% decline in the company's stock this year. Amidst a broad restructuring and divided analyst sentiment, Novo Nordisk is also engaged in a $10 billion bidding war with Pfizer for biotech firm Metsera, signaling aggressive strategic moves to regain momentum in a highly competitive sector.

Analysis

Novo Nordisk (NVO) has significantly lowered its full-year 2025 operating profit growth forecast to 4-7% in local currencies, a sharp reduction from the previous 10-16% projection. This revised outlook, coupled with Q3 sales of 75 billion DKK ($11.71 billion) that slightly missed analyst consensus, signals a challenging period for the newly appointed CEO, Mike Doustdar. The company attributes this downgrade to "lower growth expectations" for its GLP-1 treatments and slowing sales within the dynamic obesity drug market.

The competitive landscape has intensified, with Eli Lilly's (LLY) Mounjaro rapidly gaining market share, alongside pressures from copycat drugs and tighter regulatory scrutiny. This increased competition, combined with disappointing clinical results and leadership turmoil, has contributed to a more than 50% decline in NVO's stock price this year. The market's strongly negative sentiment (-0.8 for NVO) reflects these significant headwinds.

In response, Novo Nordisk is undergoing a broad restructuring aimed at improving efficiency and competitiveness. Concurrently, the company is engaged in a heated $10 billion bidding war with Pfizer (PFE) for biotech firm Metsera (MTSR), with Metsera deeming NVO's revised offer "superior." While Jefferies (JEF) downgraded NVO to "underperform" due to market share uncertainty, Berenberg maintains a positive stance, citing "peak uncertainty" and NVO's "best-in-class R&D."

Key Decisions for Investors

• Investors should re-evaluate Novo Nordisk's long-term growth trajectory given the significantly lowered profit forecast and intensifying competition in the GLP-1 market from rivals like Eli Lilly.
• Closely monitor the progress of Novo Nordisk's broad restructuring efforts and the potential integration challenges or synergies arising from the acquisition of Metsera, especially considering the ongoing legal dispute with Pfizer.
• Assess the evolving competitive dynamics, including new drug approvals, market share shifts, and regulatory developments, as these will be critical determinants of NVO's future profitability and market position.